These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 421202)

  • 1. Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro.
    Pattillo RA; Story MT; Ruckert AC
    Cancer Res; 1979 Apr; 39(4):1185-92. PubMed ID: 421202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cellular phenotypes in tumor cyst and ascitic fluid from ovarian serous carcinoma.
    Harlozinska A; Bar JK; Richter R; Cislo M
    Acta Cytol; 1992; 36(6):869-74. PubMed ID: 1449024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Density distribution and antigenic characterization of cell subpopulations isolated from cystic fluids of ovarian serous neoplasms.
    Harłozińska A; Bar JK; Rabczyński J; Noworolska A; Richter R; Cisło M
    Anticancer Res; 1989; 9(1):161-6. PubMed ID: 2705745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes.
    Melioli G; Ferrari I; Casartelli G; Ragni N
    Gynecol Oncol; 1993 Mar; 48(3):301-7. PubMed ID: 8462898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
    Shi ZL
    Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor associated antigen in ovarian carcinoma.
    Negishi Y; Mutai Y; Akiya K; Fujiwara Y; Singh G
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):126-32. PubMed ID: 6199439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor markers in ovarian cancer: tumor-associated antigens.
    Barlow JJ; Bhattacharya M
    Semin Oncol; 1975 Sep; 2(3):203-9. PubMed ID: 827023
    [No Abstract]   [Full Text] [Related]  

  • 11. Carcinoembryonic antigen in human ovarian neoplasms.
    Marchand A; Fenoglio CM; Pascal R; Richart RM; Bennett S
    Cancer Res; 1975 Dec; 35(12):3807-10. PubMed ID: 1192434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
    Rao GS; Hanjani P
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immunity and blocking factor in ovarian carcinoma.
    Mitchell MS; Kohorn EI
    Obstet Gynecol; 1976 Nov; 48(5):590-7. PubMed ID: 980285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated antigen for cystadenocarcinomas of the ovary.
    Bhattacharya M; Barlow JJ
    Natl Cancer Inst Monogr; 1975 Oct; 42():25-32. PubMed ID: 825781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological reactivity of mucinous and serous ovarian adenocarcinomas.
    Harłozińska-Szmyrka A; Slesak B; Richter R; Rabczyński J; Cisło M
    Cancer Detect Prev; 1986; 9(3-4):347-58. PubMed ID: 3017557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
    Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
    Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
    Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
    Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
    Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms.
    van Nagell JR; Pletsch QA; Goldenberg DM
    Cancer Res; 1975 Jun; 35(6):1433-7. PubMed ID: 805659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.